PURPOSE: Ga-68-labeled prostate-specific membrane antigen (PSMA) ligands have been used clinically for positron emission tomography (PET) imaging of prostate cancer. However, F-18-labeled compounds offer several advantages, including the potential for delayed imaging, high starting activities enabling multidose preparation, and improved spatial resolution in PET. For F-18 labeling of peptides conjugated with a suitable chelator, a fast and feasible method is the use of [Al(18)F](2+). In the present study, the radiofluorinations of a well-known PSMA ligand Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-HBED) via [Al(18)F](2+) were performed with respect to various reaction parameters, along with the biological evaluations in a cell experiment. PROCEDURES: [Al(18)F]PSMA-HBED was prepared by adding Na[(18)F]F into a vial containing 0.026 μmol peptide (in 0.05 M NaOAc buffer) and 0.03 μmol AlCl3⋅6H2O (in 0.05 M NaOAc buffer). Then, it was stirred at different temperatures from 1 to 30 min. Afterwards, purification was carried out by solid phase extraction. Biological evaluations were performed in PSMA-positive cell lines LNCaP C4-2, along with a negative control using PC-3 cell lines. RESULTS: The best labeling results (81 ± 0.5 %, n = 4) were observed with 0.026 μmol peptide (30 °C, 5 min). For preclinical experiments, the production of [Al(18)F]PSMA-HBED at 35 °C including purification by solid phase extraction (SPE) succeeded within 45 min, resulting in a radiochemical yield of 49 ± 1.2 % (decay-corrected, n = 6, radiochemical purity ≥98 %) at EOS. The labeled peptide revealed serum stability for 4 h as well as a promising binding coefficient (K D) value of 10.3 ± 2.2 nM in cell experiments with PSMA-positive LNCaP C4-2 cells. CONCLUSION: An efficient and one-pot method for the radiosynthesis of [Al(18)F]PSMA-HBED was developed (0.26 μmol of precursor at 35 °C). In cell culture studies, the K D suggests [Al(18)F]PSMA-HBED as a potential PSMA ligand for future investigations in vivo and clinical applications afterwards.
PURPOSE:Ga-68-labeled prostate-specific membrane antigen (PSMA) ligands have been used clinically for positron emission tomography (PET) imaging of prostate cancer. However, F-18-labeled compounds offer several advantages, including the potential for delayed imaging, high starting activities enabling multidose preparation, and improved spatial resolution in PET. For F-18 labeling of peptides conjugated with a suitable chelator, a fast and feasible method is the use of [Al(18)F](2+). In the present study, the radiofluorinations of a well-known PSMA ligand Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-HBED) via [Al(18)F](2+) were performed with respect to various reaction parameters, along with the biological evaluations in a cell experiment. PROCEDURES: [Al(18)F]PSMA-HBED was prepared by adding Na[(18)F]F into a vial containing 0.026 μmol peptide (in 0.05 M NaOAc buffer) and 0.03 μmol AlCl3⋅6H2O (in 0.05 M NaOAc buffer). Then, it was stirred at different temperatures from 1 to 30 min. Afterwards, purification was carried out by solid phase extraction. Biological evaluations were performed in PSMA-positive cell lines LNCaP C4-2, along with a negative control using PC-3 cell lines. RESULTS: The best labeling results (81 ± 0.5 %, n = 4) were observed with 0.026 μmol peptide (30 °C, 5 min). For preclinical experiments, the production of [Al(18)F]PSMA-HBED at 35 °C including purification by solid phase extraction (SPE) succeeded within 45 min, resulting in a radiochemical yield of 49 ± 1.2 % (decay-corrected, n = 6, radiochemical purity ≥98 %) at EOS. The labeled peptide revealed serum stability for 4 h as well as a promising binding coefficient (K D) value of 10.3 ± 2.2 nM in cell experiments with PSMA-positive LNCaP C4-2 cells. CONCLUSION: An efficient and one-pot method for the radiosynthesis of [Al(18)F]PSMA-HBED was developed (0.26 μmol of precursor at 35 °C). In cell culture studies, the K D suggests [Al(18)F]PSMA-HBED as a potential PSMA ligand for future investigations in vivo and clinical applications afterwards.
Entities:
Keywords:
Al18F-labeling; F-18; PSMA; PSMA-HBED; Prostate cancer
Authors: Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper Journal: Clin Cancer Res Date: 2011-10-31 Impact factor: 12.531
Authors: William J McBride; Christopher A D'Souza; Habibe Karacay; Robert M Sharkey; David M Goldenberg Journal: Bioconjug Chem Date: 2012-02-10 Impact factor: 4.774
Authors: Sumith A Kularatne; Chelvam Venkatesh; Hari-Krishna R Santhapuram; Kevin Wang; Balasubramanian Vaitilingam; Walter A Henne; Philip S Low Journal: J Med Chem Date: 2010-11-11 Impact factor: 7.446
Authors: William J McBride; Christopher A D'Souza; Robert M Sharkey; David M Goldenberg Journal: Appl Radiat Isot Date: 2011-08-23 Impact factor: 1.513
Authors: Ursula Elsässer-Beile; Gerald Reischl; Stefan Wiehr; Patrick Bühler; Philipp Wolf; Karen Alt; John Shively; Martin S Judenhofer; Hans-Jürgen Machulla; Bernd J Pichler Journal: J Nucl Med Date: 2009-03-16 Impact factor: 10.057
Authors: A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-24 Impact factor: 9.236
Authors: Robert K Doot; Anthony J Young; Margaret E Daube-Witherspoon; David Alexoff; Kyle J Labban; Hwan Lee; Zehui Wu; Zhihao Zha; Seok R Choi; Karl H Ploessl; Erin K Schubert; Hsiaoju Lee; Lin Zhu; Janet S Reddin; Joel S Karp; Hank Kung; Daniel A Pryma Journal: Nucl Med Biol Date: 2020-04-20 Impact factor: 2.408
Authors: Stefano Boschi; Jason T Lee; Seval Beykan; Roger Slavik; Liu Wei; Claudio Spick; Uta Eberlein; Andreas K Buck; Filippo Lodi; Gianfranco Cicoria; Johannes Czernin; Michael Lassmann; Stefano Fanti; Ken Herrmann Journal: Eur J Nucl Med Mol Imaging Date: 2016-06-22 Impact factor: 9.236
Authors: Christina Bluemel; Markus Krebs; Bülent Polat; Fränze Linke; Matthias Eiber; Samuel Samnick; Constantin Lapa; Michael Lassmann; Hubertus Riedmiller; Johannes Czernin; Domenico Rubello; Thorsten Bley; Saskia Kropf; Hans-Juergen Wester; Andreas K Buck; Ken Herrmann Journal: Clin Nucl Med Date: 2016-07 Impact factor: 7.794
Authors: A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper Journal: Q J Nucl Med Mol Imaging Date: 2015-07-24 Impact factor: 2.346
Authors: Vincent Bouvet; Melinda Wuest; Hans-Soenke Jans; Nancy Janzen; Afaf R Genady; John F Valliant; Francois Benard; Frank Wuest Journal: EJNMMI Res Date: 2016-05-04 Impact factor: 3.138